Definium Therapeutics Inc DFTX:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 6:03 PM EDT22.57
-1.02 (-4.31%)
-1.02 (-4.31%)Volume
26,420
Close
23.59
+0.73 (+3.19%)
+0.73 (+3.19%)Volume
2,266,062
52 week range
6.35 - 26.25
- Open22.75
- Day High23.71
- Day Low22.29
- Prev Close22.86
- 52 Week High26.25
- 52 Week High Date04/20/26
- 52 Week Low6.35
- 52 Week Low Date06/23/25
Latest On Definium Therapeutics Inc
Key Stats
- Market Cap2.573B
- Shares Out109.07M
- 10 Day Average Volume1.92M
- Dividend-
- Dividend Yield-
- Beta2.38
Latest On Definium Therapeutics Inc
KEY STATS
- Open22.75
- Day High23.71
- Day Low22.29
- Prev Close22.86
- 52 Week High26.25
- 52 Week High Date04/20/26
- 52 Week Low6.35
- 52 Week Low Date06/23/25
- Market Cap2.573B
- Shares Out109.07M
- 10 Day Average Volume1.92M
- Dividend-
- Dividend Yield-
- Beta2.38
RATIOS/PROFITABILITY
- EPS (TTM)-2.49
- P/E (TTM)-9.47
- Fwd P/E (NTM)-11.73
- EBITDA (TTM)-193.37M
- ROE (TTM)-94.70%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-
- Debt To Equity (MRQ)14.62%
EVENTS
- Earnings Date08/06/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREDefinium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The Company plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four...
Carol Vallone
Independent Chairman of the Board
Robert Barrow
Chief Executive Officer, Director
Brandi Roberts
Chief Financial Officer
Address
One World Trade Center, Suite 8500
New York, NY
10007
United States